SCHEMBL3911103

SCHEMBL3911103

NC(=O)N1CCCCC1.Nc1ccc(C(=O)O)c([N+](=O)[O-])c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
POLB P06746 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.43
ALOX15 P16050 3/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ALDH1A1 P00352 8/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PKM P14618 2/20 0.42
GAA P10253 2/20 0.42
CYP3A4 P08684 5/20 0.42
KDM4E B2RXH2 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
ESR2 Q92731 1/20 0.42
PTPN1 P18031 1/20 0.42
HTT P42858 1/20 0.41
L3MBTL3 Q96JM7 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3898845 0.86 MAPT (0.49) MAPTPOLBL3MBTL1MAPK1ALDH1A1
SCHEMBL3899956 0.86 POLB (0.49) MAPTPOLBL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3899455 0.86 POLB (0.49) MAPTPOLBL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3900886 0.84 POLB (0.47) MAPTPOLBL3MBTL1MAPK1ALDH1A1
SCHEMBL616178 0.83 ALOX15 (0.59) MAPTPOLBL3MBTL1ALOX15MAPK1
SCHEMBL3903081 0.83 LMNA (0.46) MAPTPOLBL3MBTL1MAPK1ALDH1A1
SCHEMBL3900588 0.83 MAPT (0.46) MAPTPOLBL3MBTL1MAPK1ALDH1A1
SCHEMBL3902378 0.83 POLB (0.46) MAPTPOLBL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3904110 0.83 HPD (0.52) MAPTPOLBL3MBTL1MAPK1HSD17B10
SCHEMBL3900363 0.81 POLB (0.51) MAPTPOLBL3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550492-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-23 US disclosed
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 US disclosed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
EP-1675837-A2 BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-05 EP disclosed
WO-2005012275-A2 BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-10 WO disclosed
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS CCKBR, CCKAR, GIPR MAPT 4478/4885POLB 4576/4885L3MBTL1 1202/4885
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds CCKBR, CCKAR, BRSK2 MAPT 4689/4885POLB 4671/4885L3MBTL1 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.